Primary Cell Culture Market to Peak USD 18.85 Billion by 2033

Primary Cell Culture Market Size, Trends and Growth Report (2023 - 2033)

The global primary cell culture market size was estimated at USD 5.90 billion in 2023 and is projected to grow to USD 18.85 billion by 2033, rising at a compound annual growth rate (CAGR) of 12.05% from 2024 to 2033. The growing prevalence of various chronic conditions is driving the market’s growth.

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the Primary Cell Culture Market

• By region, North America dominated the primary cell culture market by 48.21% in 2023.
• By region, Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By product, the reagents and supplements segment held the largest share of the market in 2023.
• By separation method, the enzymatic degradation segment accounted for the largest share of the market in 2023.
• By separation method, the mechanical separation segment is anticipated to grow at the fastest rate during the forecast period.
• By cell type, the animal cells segment dominated the primary cell culture market in 2023.
• By application, the cell & gene therapy development segment held the dominant share of the market in 2023.

Primary Cell Culture Market: R&D for Chronic Conditions

Primary cell culture is the process of removing cells from multicellular organisms and culturing them in ex-vivo conditions. The primary cell culture market is growing due to the growing research and development due to the growing prevalence of chronic conditions. Cell cultures are highly useful in studying the biochemistry and physiology of cells. Some of the areas in which cell cultures are used are cancer research, virology, toxicity testing, drug screening and development, vaccine production, development of bio-products, organ development, and so on. As the geriatric population grows, the demand for cell culture will also grow, which will encourage governments, key players, and different organizations to take steps to promote the growth of the primary cell culture market.

How can AI Improve the Primary Cell Culture Market?

The inclusion of AI in the primary cell culturing process promotes better outcomes. Researchers can take a co-piloted approach or make cell culture procedures completely autonomous by using AI-driven automation and decision-making. This promotes repeatability and consistency across 2D and 3D cell culture workflows in addition to standardizing procedures.

For instance,

• In July 2024, Leica Microsystems, a pioneer in microscopy and scientific equipment, introduced Mateo FL, a digital fluorescence microscope with artificial intelligence (AI) for sophisticated research applications such as cell culture checks. Mateo FL enhances the way labs approach downstream investigations involving cell culture by combining transmitted light for label-free imaging with multi-channel fluorescence and automated analysis capabilities.

Top Companies in the Primary Cell Culture Market

• Thermo Fisher Scientific, Inc.
• Bioserve India
• ATCC
• Mattek
• Corning Incorporated
• FUJIFILM Irvine Scientific, Inc.
• Lonza
• PromoCell GmbH
• Merck
• Danaher
• Axol Bioscience Ltd.

Bioserve India’s Contribution in the Primary Cell Culture Market

Toyo Seikan’s Contribution in the Primary Cell Culture Market

Cancer Research Promotes Market’s Growth

Cancer is a growing threat to society and needs continuous attention. According to the World Health Organization, lung cancer is the most common type of cancer, which led to 2.5 million new cases in 2022, followed by female breast cancer with 2.3 million new cases, colorectal cancer with 1.9 million cases, and 1.5 million new cases of prostate cancer.

The primary cell culture market is growing due to the prevalence of cancer. Primary cell cultures have wide applications in cancer research, diagnosis, development of treatment options, drug development, and so on. Primary cells may be subjected to radiation, chemicals, or viruses as part of cancer research to observe how they react. Consequently, research may be done on the changed signaling route, as well as the mechanism and etiology of cancer. These cells might potentially be used to investigate how well medications work against cancer cells.

Limited Availability is a Challenge Market

The challenges associated with discovering and obtaining primary cells for research and production in the primary cell culture market are known as the restricted availability restriction. Because primary cells are made directly from tissues and have a short lifespan, they are expensive and scarce. Small numbers of viable cells may be produced only by technically challenging isolation techniques. Tight regulatory controls, donor unpredictability, and ethical limitations further restrict their availability.

3D Culture is Promising for the Primary Cell Culture Market

The world's experts have only recently started to take an interest in 3D culture because of its rapid and promising technical advancements and several significant discoveries. Three-dimensional models of organs are more therapeutically useful since they more precisely reflect the organ in vivo condition. This leads to more accurate and predictive data being obtained from these models concerning stem cell research, drug screening, normal and malignant traits, and cell-cell interactions.

Market Segments

The Reagents & supplements Segment Dominated in 2023

By product, the reagents and supplements segment held the largest share of the primary cell culture market in 2023. Primary cells are grown in artificial conditions; therefore, it is necessary to provide all the necessary supplements for growth. Apart from this, reagents are needed for cell separation, isolation, washing, cell lysis, cell transfer, prevention of contamination, and so on.

For instance,

• In September 2023, the "Human T Cell Activation & Expansion Kit" containing microbubbles for buoyancy-activated cell sorting (BACS) was released by Akadeum Life Sciences, a leading global supplier of buoyancy-based cell separation technology. With just one easy step, the new kit can culture, activate, and remove T cells from a sample.

The Enzymatic Degradation Segment Dominated in 2023

By separation method, the enzymatic degradation segment accounted for the largest share of the primary cell culture market in 2023. The enzymes that are most frequently utilized in tissue disaggregation include crude forms of DNase, hyaluronidase, collagenase, elastase, pronase, and dispase, either alone or in different mixtures. The most common enzyme used for tissue disaggregation is crude trypsin because it is effective on a wide range of tissues and is generally well-tolerated by cells.

For instance,

• In January 2024, a global leader in professional enzyme-related goods and services, Creative Enzymes, introduced its newest product, Trypsin-Chymotrypsin, a dynamic pair of proteolytic enzymes that might lead to revolutionary progress. With the objective of enhancing diverse industrial processes, the launch represents a noteworthy advancement in the scientific field.

The Mechanical Separation Segment is the Fastest Growing

By separation method, the mechanical separation segment is anticipated to grow at the fastest rate in the primary cell culture market during the forecast period. The least complex of the three is mechanical dissociation, which includes chopping, crushing, or scraping tissue to physically rupture it. This method often involves employing a device akin to a mortar and pestle to smash the retrieved material into bits. Mechanical cell separation is quick and easy, and it is useful when working with weakly linked samples. There is no need to wait for physical separation to occur.

The Animal Cells Segment Held Largest Share in 2023

By cell type, the animal cells segment dominated the primary cell culture market in 2023. There are various applications of animal cell culture that promote its usage. For instance, for animals to produce vaccinations, animal cell cultures are utilized to multiply the viruses. Research on the impact of novel medications, chemicals, and cosmetics on the development and survival of various cell types is conducted using animal cell culture. Animal cells that have been cultured are utilized to manufacture viruses, which are then employed to make vaccinations. Gene-engineered proteins with commercial significance including insulin, hormones, monoclonal antibodies, and many more, are produced in animal cell cultures. Animal cells can be utilized to grow new organs or tissues.

The Cell & Gene Therapy Development Segment Dominated the Market

By application, the cell & gene therapy development segment held the dominant share of the primary cell culture market in 2023. Animal cell cultures can be utilized for clinical or therapeutic purposes, including genetic engineering and gene therapy. It is feasible to alter and swap out patient-derived cells for ones that have the desired working gene. An approach is to use viral vector technology to insert the missing gene or edit the genome to correct the damaged genes.

For instance,

• In May 2024, ProPharma announced that it had developed the Cell Production Box (CF Box), an enclosed, fully automated system for cell production, in partnership with PBL. This unique, cutting-edge technology enables the decentralized manufacture of all sorts of Cell & Gene Therapies (CAGT) at Class D (ISO8) or c.n.c. adjacent areas. With a high level of automation and widely accepted AI technology, the CF Box greatly minimizes the need for expensive clean rooms and manual labor.

North America’s NIH Will Invest $30M in Primary Care Research

By region, North America dominated the primary cell culture market by 48.21% in 2023. Many factors, such as the high expense of healthcare, the aging population, the increased incidence of chronic illnesses, and government support, are blamed for the Region's growth. The market's growth in the area is also being aided by industry participants' increasing focus on developing cutting-edge uses for equipment, cell culture, easy access to a variety of cell kinds, and interactions between cells.

The U.S. government is supporting the growth of the primary cell culture via various investments. The U.S. regulators are also supporting organizations that are using cell culture to develop new products.

For instance,

• In June 2024, in order to develop a national primary care research network that combines clinical research and community-based primary care, the National Institutes of Health (NIH) will invest around $30 million over the course of the fiscal years 2024-2125. Advancing Research Equity for Health (CARE for Health) is a recently founded program that aims to improve access to clinical research to inform medical care, especially for members of historically underrepresented or low-income populations.
• In June 2023, the sale of chicken derived from animal cells was authorized by US regulators on Wednesday for the first time, enabling two Californian businesses to bring "lab-grown" poultry to restaurant tables and, eventually, grocery stores throughout the country.

Apart from this, the growing prevalence of cancer in the U.S. is boosting the primary cell culture market’s growth. Cell cultures are highly useful in various research and development associated with cancer.

Key Players Promoting Market Growth in Asia Pacific

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. The Asia Pacific area has become a prominent participant in the cell culture sector, which has experienced enormous development in recent years. Growing demand for biopharmaceuticals, increased funding for life sciences research, and advancements in healthcare infrastructure are driving the market.

For instance,

• In May 2024, the DBT-BUILDER Primary Cell Culture Lab Facility will soon open on the Osmania University (OU) campus. It belongs to the Department of Biology. The University of Birmingham's DBT-BUILDER-Interdisciplinary Life Science Programme for Advanced Research and Education will be funded over the course of five years with an award of Rs 8.03 crore. The Indian government's Department of Biotechnology is the source of funding.

Recent Developments in the Primary Cell Culture Market

• In July 2023, a production factory for cell culture medium was added to Sartorius, a leading worldwide partner in life science research and the biopharmaceutical industry, at its existing location in Yauco, Puerto Rico. Today marked the formal opening of the 21,500-square-foot (2,000-square-meter) facility, which will primarily serve clients throughout the Americas. This will expand the company's capacity to produce cell culture media.
• In July 2023, Lonza unveiled the TheraPRO® CHO Media System, a ground-breaking platform for cell culture that optimizes output and protein quality while streamlining processes using GS-CHO cell lines. For biotechnology and pharmaceutical companies that produce therapeutic proteins, the launch benefits by shortening time-to-market and enhancing product quality.

Segments Covered in the Report

By Product

• Primary Cells
  • Fat
  • Blood
  • Nerve
  • Bone
  • Endothelial
  • Skin
  • Muscle
  • Stem
  • Others
• Reagents and Supplements
  • Attachment Solution
  • Buffers and Salts
  • Freezing Media
  • Sera
  • Growth Factors and Cytokines
• Media
  • Fat Cells Media
  • Blood Cells Media
  • Nerve Cells Media
  • Bone Cells Media
  • Endothelial Cells Media
  • Skin Cells Media
  • Muscle Cells Media
  • Stem Cells Media
  • Others

By Separation Method

• Explant Method
• Enzymatic Degradation
  • Trypsin
  • Collagenase
  • Protease
  • Pronase
  • Dispase
  • Hyaluronidase
  • Neuraminidase
  • Elastase
  • DNase
  • Papain
  • Accutase
  • Others
• Mechanical Separation
• Others

By Cell Type

• Animal Cells
• Human Cells

By Application

• Cell & Gene Therapy Development
• Vaccine Production
• Model System
• Virology
• Prenatal Diagnosis
• Others

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait